Literature DB >> 12190159

Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions.

Walter L Straus1, Joshua J Ofman, Catherine MacLean, Sally Morton, Marc L Berger, Elizabeth A Roth, Paul Shekelle.   

Abstract

OBJECTIVE: Nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with dyspepsia, but the relationship is obscured by variations in the terminology used to report GI symptoms. Using alternative definitions, we assessed the relationship between NSAID use and dyspepsia.
METHODS: We searched MEDLINE, EMBASE, HEALTHSTAR, and BIOSIS databases (1966-1997) and New Drug Application reviews, identifying randomized, placebo-controlled trials (5 days or more duration) of any NSAID, reporting original data on GI complications. Based upon reported terms describing upper GI symptoms, we derived three definitions: strict, using terms synonymous with epigastric pain/discomfort; loose, (containing the strict definition plus terms for heartburn, nausea, bloating, anorexia, and vomiting); and a loose definition without heartburn terms (the loose-less-heartburn definition). Using each definition, we performed a random-effects model meta-analysis of the relationship between NSAID exposure and dyspepsia.
RESULTS: Fifty-five published and 37 unpublished controlled NSAID trials met our inclusion criteria. The mean duration of the trials was 33.2 days (SD 40 days). Application of the strict definition resulted in a pooled risk ratio of dyspepsia for NSAIDs compared with placebo of 1.36 (95% CI = 1.11-1.67). For the loose definition, the pooled risk ratio was 1.13 (95% CI = 0.98-1.32). The loose-less-heartburn definition yielded a pooled risk ratio of 1.19 (95% CI = 1.03-1.39). In the placebo-treated control groups, the percent of patients reporting dyspepsia ranged from 2.3% (strict definition) to 4.2% (loose and loose-less-heartburn definitions).
CONCLUSIONS: Using the strict definition, based solely on epigastric pain-related symptoms, NSAIDs increased the risk of dyspepsia by 36% (p < 0.05). These findings may be useful in creating a standardized definition of NSAID-related dyspepsia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12190159     DOI: 10.1111/j.1572-0241.2002.05905.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

1.  Evidence-based clinical practice guidelines for functional dyspepsia.

Authors:  Hiroto Miwa; Motoyasu Kusano; Tomiyasu Arisawa; Tadayuki Oshima; Mototsugu Kato; Takashi Joh; Hidekazu Suzuki; Kazunari Tominaga; Koji Nakada; Akihito Nagahara; Seiji Futagami; Noriaki Manabe; Akio Inui; Ken Haruma; Kazuhide Higuchi; Koji Yakabi; Michio Hongo; Naomi Uemura; Yoshikazu Kinoshita; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2015-01-14       Impact factor: 7.527

2.  Effects of chronic therapy with non-steroidal antiinflammatory drugs on gastric permeability of sucrose: a study on 71 patients with rheumatoid arthritis.

Authors:  Marta Maino; Nicola Mantovani; Roberta Merli; Giulia Martina Cavestro; Gioacchino Leandro; Lucas Giovanni Cavallaro; Vincenzo Corrente; Veronica Iori; Alberto Pilotto; Angelo Franzè; Francesco Di Mario
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

Review 3.  NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options.

Authors:  Jørgen Naesdal; Kurt Brown
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  Non-steroidal anti-inflammatory drugs and gastroprotection with proton pump inhibitors: a focus on ketoprofen/omeprazole.

Authors:  Antonio Gigante; Ignacio Tagarro
Journal:  Clin Drug Investig       Date:  2012-04-01       Impact factor: 2.859

Review 5.  Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury.

Authors:  B H McCarberg; C E Argoff
Journal:  Int J Clin Pract       Date:  2010-10       Impact factor: 2.503

6.  Esomeprazole for the management of upper gastrointestinal symptoms in patients who require NSAIDs: a review of the NASA and SPACE double-blind, placebo-controlled studies.

Authors:  Christopher J Hawkey; Lars-Erik Svedberg; Jørgen Naesdal; Claire Byrne
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

7.  Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study.

Authors:  Mohammad Bakhriansyah; Patrick C Souverein; Anthonius de Boer; Olaf H Klungel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-03-31       Impact factor: 2.890

8.  Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials.

Authors:  John A Baron; Stephen Senn; Michael Voelker; Angel Lanas; Irene Laurora; Wolfgang Thielemann; Andreas Brückner; Denis McCarthy
Journal:  Drugs R D       Date:  2013-03

9.  Prevalence of gastroesophageal reflux disease symptoms and related factors in patients with rheumatoid arthritis.

Authors:  Akihide Nampei; Kenrin Shi; Kosuke Ebina; Tetsuya Tomita; Kazuomi Sugamoto; Hideki Yoshikawa; Makoto Hirao; Jun Hashimoto
Journal:  J Clin Biochem Nutr       Date:  2013-02-06       Impact factor: 3.114

10.  Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies.

Authors:  Christopher J Hawkey; Nicholas J Talley; James M Scheiman; Roger H Jones; Göran Långström; Jorgen Naesdal; Neville D Yeomans
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.